Nancy Stagliano, Ph.D., is an accomplished serial biotechnology entrepreneur. As chief executive officer, Dr. Stagliano has successfully launched and/or exited three consecutive biotech companies: CytomX Therapeutics (CTMX), iPierian and, most recently, True North Therapeutics. As chief executive officer and co-founder of True North Therapeutics, Dr. Stagliano led the company to its recent acquisition by Bioverativ, Inc. for a total deal value of up to $825 million. Under her leadership, True North discovered and developed a first-in-class monoclonal antibody in the classical complement pathway TNT009, which received breakthrough therapy designation from the U.S. Food & Drug Administration for the orphan indication, Cold Agglutinin Disease.
Previously, Dr. Stagliano was chief executive officer of iPierian, Inc., which applied human iPSCs to model neurodegenerative diseases. The company and its lead antibody program against Tau for the treatment of progressive supranuclear palsy (PSP) and Alzheimer’s disease were acquired by Bristol-Myers Squibb in April of 2014 for a total deal value of $725 million; the antibody is currently in a Phase 2 trial in PSP led by Biogen. From 2008–2010, Dr. Stagliano was the chief executive officer and co-founder of CytomX Therapeutics and a lead inventor on the CytomX Probody platform. Before moving to California, Dr. Stagliano worked in Cambridge, Mass., where she had an eight-year tenure at Millennium Pharmaceuticals.
Dr. Stagliano received her bachelor of science degree in electrical engineering and master of science degree in biomedical engineering from Drexel University in Philadelphia. She obtained her doctor of philosophy degree in neuroscience from the University of Miami, Miller School of Medicine, in Miami.